JP2012521191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521191A5 JP2012521191A5 JP2011551173A JP2011551173A JP2012521191A5 JP 2012521191 A5 JP2012521191 A5 JP 2012521191A5 JP 2011551173 A JP2011551173 A JP 2011551173A JP 2011551173 A JP2011551173 A JP 2011551173A JP 2012521191 A5 JP2012521191 A5 JP 2012521191A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence provided
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003042 antagnostic effect Effects 0.000 claims 12
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 7
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 7
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 6
- 102000050320 human TNFRSF4 Human genes 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000001575 pathological effect Effects 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 229920001427 mPEG Polymers 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000010367 cloning Methods 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920002859 polyalkenylene Polymers 0.000 claims 1
- 229920001281 polyalkylene Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15303809P | 2009-02-17 | 2009-02-17 | |
| US61/153,038 | 2009-02-17 | ||
| PCT/US2010/024377 WO2010096418A2 (en) | 2009-02-17 | 2010-02-17 | Antibody molecules having specificity for human ox40 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015063849A Division JP2015171362A (ja) | 2009-02-17 | 2015-03-26 | ヒトox40に対する特異性を有する抗体分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012521191A JP2012521191A (ja) | 2012-09-13 |
| JP2012521191A5 true JP2012521191A5 (https=) | 2014-04-17 |
| JP5782385B2 JP5782385B2 (ja) | 2015-09-24 |
Family
ID=42634416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011551173A Expired - Fee Related JP5782385B2 (ja) | 2009-02-17 | 2010-02-17 | ヒトox40に対する特異性を有する抗体分子 |
| JP2015063849A Pending JP2015171362A (ja) | 2009-02-17 | 2015-03-26 | ヒトox40に対する特異性を有する抗体分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015063849A Pending JP2015171362A (ja) | 2009-02-17 | 2015-03-26 | ヒトox40に対する特異性を有する抗体分子 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US8614295B2 (https=) |
| EP (1) | EP2398498B1 (https=) |
| JP (2) | JP5782385B2 (https=) |
| KR (1) | KR101761929B1 (https=) |
| CN (1) | CN102741287B (https=) |
| AR (1) | AR075504A1 (https=) |
| AU (1) | AU2010216152B2 (https=) |
| BR (1) | BRPI1008692B8 (https=) |
| CA (1) | CA2751477C (https=) |
| CL (1) | CL2011001994A1 (https=) |
| CO (1) | CO6410312A2 (https=) |
| CY (1) | CY1121431T1 (https=) |
| DK (1) | DK2398498T3 (https=) |
| EA (1) | EA037792B1 (https=) |
| ES (1) | ES2699716T3 (https=) |
| HR (1) | HRP20181932T1 (https=) |
| HU (1) | HUE042114T2 (https=) |
| IL (1) | IL214282A (https=) |
| LT (1) | LT2398498T (https=) |
| MA (1) | MA33122B1 (https=) |
| MX (1) | MX2011008697A (https=) |
| MY (1) | MY157473A (https=) |
| NZ (1) | NZ594315A (https=) |
| PE (1) | PE20120211A1 (https=) |
| PL (1) | PL2398498T3 (https=) |
| PT (1) | PT2398498T (https=) |
| SG (3) | SG173620A1 (https=) |
| SI (1) | SI2398498T1 (https=) |
| TN (1) | TN2011000374A1 (https=) |
| TW (1) | TWI476281B (https=) |
| UA (1) | UA107341C2 (https=) |
| UY (1) | UY32451A (https=) |
| WO (1) | WO2010096418A2 (https=) |
| ZA (1) | ZA201105500B (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8614295B2 (en) * | 2009-02-17 | 2013-12-24 | Ucb Pharma S.A. | Antibody molecules having specificity for human OX40 |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| SMT201700185T1 (it) | 2010-08-23 | 2017-05-08 | Univ Texas | Anticorpi anti-ox40 e metodi di uso degli stessi |
| US9428567B2 (en) | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
| AP2014007415A0 (en) * | 2011-07-11 | 2014-02-28 | Glenmark Pharmaceuticals Sa | Antibodies that bind to OX40 and their uses |
| CA2845810C (en) * | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| AU2012335496B2 (en) | 2011-11-11 | 2017-05-11 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| WO2013086419A1 (en) * | 2011-12-09 | 2013-06-13 | California Institute Of Technology | Polymer scaffolds and their use in the treatment of vision loss |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| SMT201800503T1 (it) | 2013-03-18 | 2018-11-09 | Janssen Pharmaceuticals Inc | Anticorpi anti-cd (ox40) umanizzati e loro usi |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| AU2015228372B2 (en) * | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| EP3322443A1 (en) * | 2015-07-13 | 2018-05-23 | Yeda Research and Development Co. Ltd | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| KR101819135B1 (ko) * | 2014-03-18 | 2018-01-18 | 한국과학기술원 | 당화 vegf 디코이 수용체 융합 단백질 |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| SG10201912986PA (en) | 2014-05-28 | 2020-02-27 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
| EP3623386B1 (en) * | 2015-01-08 | 2022-04-13 | BioNTech SE | Agonistic tnf receptor binding agents |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| MX2017011194A (es) | 2015-03-03 | 2018-04-10 | Kymab Ltd | Anticuerpos, usos y métodos. |
| US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| GB201506868D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| CA2984794A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| TN2019000101A1 (en) | 2015-05-29 | 2020-07-15 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof. |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| WO2017063162A1 (zh) * | 2015-10-15 | 2017-04-20 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| WO2017123673A2 (en) | 2016-01-11 | 2017-07-20 | Inhibrx Lp | Multivalent and multispecific ox40-binding fusion proteins |
| WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| CN110088132B (zh) | 2016-08-17 | 2020-10-27 | 康姆普根有限公司 | 抗tigit抗体,抗pvrig抗体及其组合 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN110799213A (zh) | 2017-06-01 | 2020-02-14 | 康姆普根有限公司 | 三联组合抗体疗法 |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| WO2019173780A2 (en) * | 2018-03-08 | 2019-09-12 | Magenta Therapeutics, Inc. | Anti-cd252 antibodies, conjugates, and methods of use |
| CN112638375A (zh) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | 通过后细胞信号传导因子的调节来增加免疫活性 |
| EP3823594B1 (en) | 2018-07-19 | 2025-02-05 | Ichnos Sciences S.A. | Liquid antibody formulation |
| AR114552A1 (es) | 2018-08-13 | 2020-09-16 | Inhibrx Inc | Polipéptidos de unión a ox40 y sus usos |
| EP3860653A1 (en) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| EP3766481A1 (en) * | 2019-07-19 | 2021-01-20 | Ichnos Sciences SA | Liquid antibody formulation |
| MX2022007712A (es) | 2019-12-17 | 2022-09-26 | Amgen Inc | Agonista doble de interleucina-2/receptor de tnf para uso en terapia. |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US20250339522A1 (en) | 2021-10-15 | 2025-11-06 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
| US20250249278A1 (en) | 2022-04-14 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| US12195546B2 (en) * | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| TW202523691A (zh) * | 2023-10-06 | 2025-06-16 | 瑞士商伊克諾斯科學公司 | 親和力成熟之抗-ox40抗體及其用途 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5821332A (en) * | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| GB0123276D0 (en) | 2001-09-27 | 2001-11-21 | Imp College Innovations Ltd | Uses of agents that bind immune-system components |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| AU2002365814A1 (en) | 2001-12-18 | 2003-07-30 | J And J Research Pty Ltd | Method of treating asthma |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| US7993864B2 (en) | 2002-12-03 | 2011-08-09 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CA2528903C (en) * | 2004-12-20 | 2008-01-15 | Honda Motor Co., Ltd. | Braking device for motorcycle |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
| EP2314619A1 (en) | 2005-12-05 | 2011-04-27 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
| EP2010207A4 (en) | 2006-03-22 | 2009-12-02 | Imp Innovations Ltd | COMPOSITIONS AND METHODS RELATING TO THE MODULATION OF COMPONENTS OF THE IMMUNE SYSTEM |
| WO2007112054A2 (en) | 2006-03-23 | 2007-10-04 | Sea Lane Biotechnologies, Llc | Facilitation of translocation of molecules through the gastrointestinal tract |
| US20100136030A1 (en) * | 2007-02-27 | 2010-06-03 | Lamhamedi-Cherradi Salah-Eddine | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| WO2009040562A1 (en) | 2007-09-26 | 2009-04-02 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| DK2851374T3 (en) | 2007-12-14 | 2017-06-19 | Bristol Myers Squibb Co | Binding molecules to the human OX40 receptor |
| US8614295B2 (en) | 2009-02-17 | 2013-12-24 | Ucb Pharma S.A. | Antibody molecules having specificity for human OX40 |
| US20120283415A1 (en) * | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
| GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) * | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| AP2014007415A0 (en) * | 2011-07-11 | 2014-02-28 | Glenmark Pharmaceuticals Sa | Antibodies that bind to OX40 and their uses |
| UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
-
2010
- 2010-02-17 US US12/706,993 patent/US8614295B2/en not_active Expired - Fee Related
- 2010-02-17 CN CN201080017854.0A patent/CN102741287B/zh not_active Expired - Fee Related
- 2010-02-17 HU HUE10744211A patent/HUE042114T2/hu unknown
- 2010-02-17 EP EP10744211.3A patent/EP2398498B1/en active Active
- 2010-02-17 CA CA2751477A patent/CA2751477C/en active Active
- 2010-02-17 UY UY0001032451A patent/UY32451A/es not_active Application Discontinuation
- 2010-02-17 MA MA34167A patent/MA33122B1/fr unknown
- 2010-02-17 KR KR1020117021615A patent/KR101761929B1/ko not_active Expired - Fee Related
- 2010-02-17 WO PCT/US2010/024377 patent/WO2010096418A2/en not_active Ceased
- 2010-02-17 ES ES10744211T patent/ES2699716T3/es active Active
- 2010-02-17 LT LTEP10744211.3T patent/LT2398498T/lt unknown
- 2010-02-17 MY MYPI2011003526A patent/MY157473A/en unknown
- 2010-02-17 AR ARP100100457A patent/AR075504A1/es active IP Right Grant
- 2010-02-17 SG SG2011057528A patent/SG173620A1/en unknown
- 2010-02-17 PT PT10744211T patent/PT2398498T/pt unknown
- 2010-02-17 MX MX2011008697A patent/MX2011008697A/es active IP Right Grant
- 2010-02-17 AU AU2010216152A patent/AU2010216152B2/en not_active Ceased
- 2010-02-17 NZ NZ594315A patent/NZ594315A/xx not_active IP Right Cessation
- 2010-02-17 SG SG10201505038TA patent/SG10201505038TA/en unknown
- 2010-02-17 BR BRPI1008692A patent/BRPI1008692B8/pt not_active IP Right Cessation
- 2010-02-17 PL PL10744211T patent/PL2398498T3/pl unknown
- 2010-02-17 JP JP2011551173A patent/JP5782385B2/ja not_active Expired - Fee Related
- 2010-02-17 SI SI201031802T patent/SI2398498T1/sl unknown
- 2010-02-17 PE PE2011001494A patent/PE20120211A1/es not_active Application Discontinuation
- 2010-02-17 UA UAA201111078A patent/UA107341C2/uk unknown
- 2010-02-17 HR HRP20181932TT patent/HRP20181932T1/hr unknown
- 2010-02-17 EA EA201171060A patent/EA037792B1/ru unknown
- 2010-02-17 DK DK10744211.3T patent/DK2398498T3/en active
- 2010-02-17 SG SG2014014708A patent/SG2014014708A/en unknown
- 2010-02-22 TW TW099104929A patent/TWI476281B/zh not_active IP Right Cessation
-
2011
- 2011-07-25 IL IL214282A patent/IL214282A/en active IP Right Grant
- 2011-07-26 ZA ZA2011/05500A patent/ZA201105500B/en unknown
- 2011-08-02 TN TN2011000374A patent/TN2011000374A1/fr unknown
- 2011-08-08 CO CO11100099A patent/CO6410312A2/es active IP Right Grant
- 2011-08-16 CL CL2011001994A patent/CL2011001994A1/es unknown
-
2013
- 2013-08-22 US US13/973,189 patent/US9428570B2/en active Active
-
2015
- 2015-03-26 JP JP2015063849A patent/JP2015171362A/ja active Pending
-
2016
- 2016-08-19 US US15/242,135 patent/US10017575B2/en active Active
-
2018
- 2018-12-04 CY CY20181101288T patent/CY1121431T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012521191A5 (https=) | ||
| US12428497B2 (en) | Multispecific antibody constructs | |
| RU2018146158A (ru) | Антитела | |
| JP2009225799A5 (https=) | ||
| JP2018526981A5 (https=) | ||
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| JP2011527902A5 (https=) | ||
| JP2011504501A5 (https=) | ||
| JP2012501670A5 (https=) | ||
| JP2017533694A5 (https=) | ||
| JP2019515646A5 (https=) | ||
| JP2013545455A5 (https=) | ||
| JP2012501669A5 (https=) | ||
| JP2015519375A5 (https=) | ||
| JP2013519364A5 (https=) | ||
| JP2010501164A5 (https=) | ||
| JP2014529610A5 (https=) | ||
| JP2015517492A5 (https=) | ||
| JP2019505565A5 (https=) | ||
| JP2018508218A5 (https=) | ||
| JP2016006052A5 (https=) | ||
| JP7689125B2 (ja) | ヒトil-13及びil-17に対する結合特異性を有する多重特異性抗体 | |
| CN114829398B (zh) | 对人il-13具有结合特异性的抗体 | |
| CA3164234A1 (en) | Multi-specific antibodies | |
| RU2018126315A (ru) | Молекулы антител, которые связываются с tnf-альфа |